Implications and emerging control strategies for ventilator-associated infections

Expert Review of Anti-Infective Therapy

Volumn 13, Issue 3, 2015, Pages 379-393

  Loo, Ching Yee ^a,b   Lee, Wing Hin ^a,b   Young, Paul M ^b   Cavaliere, Rosalia ^c   Whitchurch, Cynthia B ^c   Rohanizadeh, Ramin ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

Author keywords

biofilm; Pseudomonas aeruginosa; silver nanoparticle; Staphylococcus aureus; surface modification; Ventilator associated pneumonia

Indexed keywords

ANTIBIOTIC AGENT; BIOCIDE; DISPERSANT; SILVER NANOPARTICLE; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; ARTIFICIAL VENTILATION; BACTERIAL CELL; BACTERIAL CLEARANCE; BACTERIAL COLONIZATION; BACTERIAL GROWTH; BACTERIUM ADHERENCE; BIOFILM; DRUG SELECTIVITY; ENDOTRACHEAL TUBE; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; INFECTION PREVENTION; MATERIAL COATING; NONHUMAN; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; SURFACE PROPERTY; ULTRASOUND THERAPY; VENTILATOR ASSOCIATED PNEUMONIA; ADVERSE EFFECTS; ENDOTRACHEAL INTUBATION; INTENSIVE CARE UNIT; MECHANICAL VENTILATOR; MICROBIOLOGY; PATHOGENICITY;

ANTI-BACTERIAL AGENTS; BIOFILMS; HUMANS; INTENSIVE CARE UNITS; INTUBATION, INTRATRACHEAL; PNEUMONIA, VENTILATOR-ASSOCIATED; PSEUDOMONAS AERUGINOSA; RESPIRATION, ARTIFICIAL; STAPHYLOCOCCUS AUREUS; VENTILATORS, MECHANICAL;

EID: 84923037865     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.2015.1007045     Document Type: Article

References (128)

1. Chastre J, Fagon J-Y. Ventilator-associated Pneumonia. Am J Respir Crit Care Med 2002;165:867-903
2. Koulenti D, Rello J. Hospital-acquired pneumonia in the 21st century: a review of existing treatment options and their impact on patient care. Expert Opin Pharmacother 2006;7(12):1555-69
3. Madani N, Rosenthal V, Dendane T, et al. Health-care associated infections rates, length of stay, and bacterial resistance in an intensive care unit of Morocco: findings of the International Nosocomial Infection Control Consortium (INICC). Int Arch Med 2009;2(1):29
4. Kü bler A, Duszynska W, Rosenthal VD, et al. Device-associated infection rates and extra length of stay in an intensive care unit of a university hospital in Wroclaw, Poland: international Nosocomial Infection Control Consortium's (INICC) findings. J Crit Care 2012;27(1):105.e105-10
5. Guanche-Garcell H, Morales-Pérez C, Rosenthal VD. Effectiveness of a multidimensional approach for the prevention of ventilator-associated pneumonia in an adult intensive care unit in Cuba: findings of the International Nosocomial Infection Control Consortium (INICC). J Infect Public Health 2013;6(2):98-107
6. Leblebicioglu H, Yalcin AN, Rosenthal VD, et al. Effectiveness of a multidimensional approach for prevention of ventilator-associated pneumonia in 11 adult intensive care units from 10 cities of Turkey: findings of the International Nosocomial Infection Control Consortium (INICC). Infection 2013;41(2):447-56
7. Rosenthal VD, Maki DG, Mehta Y, et al. International Nosocomial Infection Control Consortiu (INICC) report, data summary of 43 countries for 2007-2012. Device-associated module. Am J Infect Control 2014;42(9):942-56
8. Cuellar LE, Fernandez-Maldonado E, Rosenthal VD, et al. Device-associated infection rates and mortality in intensive care units of Peruvian hospitals: findings of the International Nosocomial Infection Control Consortium. Rev Panam Salud Publica 2008;24(1):16-24
9. Guanche-Garcell H, Requejo-Pino O, Rosenthal VD, et al. Device-associated infection rates in adult intensive care units of Cuban university hospitals: international Nosocomial Infection Control Consortium (INICC) findings. Int J Infect Dis 2011;15(5):e357-62
10. Hu B, Tao L, Rosenthal VD, et al. Device-associated infection rates, device use, length of stay, and mortality in intensive care units of 4 Chinese hospitals: international Nosocomial Control Consortium findings. Am J Infect Control 2013;41(4):301-6
11. Pneumatikos IA, Dragoumanis CK, Bouros DE. Ventilator-associated pneumonia or endotracheal tube-associated pneumonia?: an approach to the pathogenesis and preventive strategies emphasizing the importance of endotracheal tube. Anesthesiology 2009;110(3):673-80
12. Sathishkumar S, Fassl J. Endotracheal tube-associated pneumonia. Anesthesiology 2009;111(4):922
13. Kollef MH. Prevention of hospital-associated pneumonia and ventilator-associated pneumonia. Crit Care Med 2004;32(6):1396-405
14. Rello J, Soñora R, Jubert P, et al. Pneumonia in intubated patients: role of respiratory airway care. Am J Respir Crit Care Med 1996;154(1):111-15
15. Levine SA, Niederman MS. The impact of tracheal intubation on host defenses and risks for nosocomial pneumonia. Clin Chest Med 1991;12(3):523-43
16. Feldman C, Kassel M, Cantrell J, et al. The presence and sequence of endotracheal tube colonization in patients undergoing mechanical ventilation. Eur Respir J 1999;13(3):546-51
17. Rubenstein JS, Kabat K, Shulman ST, Yogev R. Bacterial and fungal colonization of endotracheal tubes in children: a prospective study. Crit Care Med 1992;20(11):1544-9
18. Ibrahim EH, Tracy L, Hill C, et al. The occurrence of ventilator-associated pneumonia in a community hospital - risk factors and clinical outcomes. Chest 2001;120:555-61
19. Torres A, Carlet J, Bouza E, et al. Ventilator-associated pneumonia. Eur Respir J 2001;17(5):1034-45
20. Torres A, Ewig S, Lode H, et al. Defining, treating and preventing hospital acquired pneumonia: european perspective. Intensive Care Med 2009;35(1):9-29
21. Rello J, Lode H, Cornaglia G, et al. A European care bundle for prevention of ventilator-associated pneumonia. Intensive Care Med 2010;36(5):773-80
22. Muscedere J, Dodek P, Keenan S, et al. Comprehensive evidence-based clinical practice guidelines for ventilator-associated pneumonia: prevention. J Crit Care 2008;23(1):126-37
23. Berwick DM, Calkins DR, McCannon C, Hackbarth AD. The 100 000 lives campaign: setting a goal and a deadline for improving health care quality. JAMA 2006;295(3):324-7
24. Lorente L, Blot S, Rello J. New issues and controversies in the prevention of ventilator-associated pneumonia. Am J Respir Crit Care Med 2010;182(7):870-6
25. Drenkard E. Antimicrobial resistance of Pseudomonas aeruginosa biofilms. Microbes Infect 2003;5(13):1213-19
26. Walters MC, Roe F, Bugnicourt A, et al. Contributions of antibiotic penetration, oxygen limitation, and low metabolic activity to tolerance of Pseudomonas aeruginosa biofilms to ciprofloxacin and tobramycin. Antimicrob Agents Chemother 2003;47(1):317-23
27. Fernández L, Breidenstein EBM, Hancock REW. Creeping baselines and adaptive resistance to antibiotics. Drug Resist Updat 2011;14(1):1-21
28. Ortíz-Pérez A, Martín-de-Hijas N, Alonso-Rodríguez N, et al. Importance of antibiotic penetration in the antimicrobial resistance of biofilm formed by non-pigmented rapidly growing mycobacteria against amikacin, ciprofloxacin and clarithromycin. Enferm Infecc Microbiol Clin 2011;29(2):79-84
29. Loo CY, Young PM, Lee WH, et al. Super-hydrophobic nanotextured polyvinyl chloride films for delaying Pseudomonas aeruginosa attachment to intubation tubes and medical plastics. Acta Biomater 2012;8(5):1881-90
30. Zhang W, Chu PK, Ji J, et al. Plasma surface modification of poly vinyl chloride for improvement of antibacterial properties. Biomaterials 2006;27(1):44-51
31. Xu LC, Siedlecki CA. Submicron-textured biomaterial surface reduces staphylococcal bacterial adhesion and biofilm formation. Acta Biomater 2012;8(1):72-81
32. Hoffman M, May RM, Reddy ST. Micro-Patterned Surfaces for Reducing Biofilm Formation in an Endotracheal-Tube-Like Environment. Am J Infect Control 2012;40(5):e59-60
33. Durmus NG, Taylor EN, Inci F, et al. Fructose-enhanced reduction of bacterial growth on nanorough surfaces. Int J Nanomedicine 2012;7:537-45
34. Seil JT, Webster TJ. Reduced Staphylococcus aureus proliferation and biofilm formation on zinc oxide nanoparticle PVC composite surfaces. Acta Biomater 2011;7(6):2579-84
35. Seil JT, Rubien NM, Webster TJ, Tarquinio KM. Comparison of quantification methods illustrates reduced Pseudomonas aeruginosa activity on nanorough polyvinyl chloride. J Biomed Mater Res B Appl Biomater 2011;98B(1):1-7
36. Loo CY, Young PM, Cavaliere R, et al. Silver nanoparticles enhance Pseudomonas aeruginosa PAO1 biofilm detachment. Drug Dev Ind Pharm 2014;40(6):719-29
37. Martinez-Gutierrez F, Boegli L, Agostinho A, et al. Anti-biofilm activity of silver nanoparticles against different microorganisms. Biofouling 2013;29(6):651-60
38. Cafiso V, Bertuccio T, Spina D, et al. Tigecycline inhibition of a mature biofilm in clinical isolates of Staphylococcus aureus: comparison with other drugs. FEMS Immunol Med Microbiol 2010;59(3):466-9
39. Niepa THR, Gilbert JL, Ren DC. Controlling Pseudomonas aeruginosa persister cells by weak electrochemical currents and synergistic effects with tobramycin. Biomaterials 2012;33(30):7356-65
40. Norris P, Noble M, Francolini I, et al. Ultrasonically controlled release of ciprofloxacin from self-assembled coatings on poly(2-hydroxyethyl methacrylate) hydrogels for Pseudomonas aeruginosa biofilm prevention. Antimicrob Agents Chemother 2005;49(10):4272-9
41. O'Toole GA. To build a biofilm. J Bacteriol 2003;185(9):2687-9
42. Stover CK, Pham XQ, Erwin AL, et al. Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature 2000;406(6799):959-64
43. Palmer RJ, White DC. Developmental biology of biofilms: implications for treatment and control. Trends Microbiol 1997;5(11):435-40
44. Hori K, Matsumoto S. Bacterial adhesion: from mechanism to control. Biochem Eng J 2010;48(3):424-34
45. Hiemenz PC, Rajagopalan R. Principles in colloid and surface chemistry. Marcel Dekker; New York: 1997
46. Loosdrecht MM, Lyklema J, Norde W, Zehnder AB. Bacterial adhesion: a physicochemical approach. Microb Ecol 1989;17(1):1-15
47. Ong YL, Razatos A, Georgiou G, Sharma MM. Adhesion forces between E-coli bacteria and biomaterial surfaces. Langmuir 1999;15(8):2719-25
48. O'Toole GA, Kolter R. Flagellar and twitching motility are necessary for Pseudomonas aeruginosa biofilm development. Mol Microbiol 1998;30(2):295-304
49. Tsuneda S, Aikawa H, Hayashi H, et al. Extracellular polymeric substances responsible for bacterial adhesion onto solid surface. Fems Microbiol Lett 2003;223(2):287-92
50. Flemming HC, Wingender J. Relevance of microbial extracellular polymeric substances (EPSs) - Part II: technical aspects. Water Sci Technol 2001;43(6):9-16
51. Flemming HC, Wingender J. Relevance of microbial extracellular polymeric substances (EPSs) - Part I: structural and ecological aspects. Water Sci Technol 2001;43(6):1-8
52. Sievert DMP, Ricks PP, Edwards JRMS, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol 2013;34(1):1-14
53. Leblebicioglu H, Rosenthal VD, Arikan Ö A, et al. Device-associated hospital-acquired infection rates in Turkish intensive care units. Findings of the International Nosocomial Infection Control Consortium (INICC). J Hosp Infect 2007;65(3):251-7
54. Barrett S. Infection control in Britain. J Hosp Infect 2002;50:106-9
55. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004;32:470-85
56. Haley R, Morgan W, Culver D, et al. Update from the SENIC project. Hospital infection control: recent progress and opportunities under prospective payment. Am J Infect Control 1985;13:97-108
57. Cooke E, Coello R, Sedgwick J, et al. A national surveillance scheme for hospital associated infections in England. Team of the Nosocomial Infection National Surveillance Scheme. J Hosp Infect 2000;46:1-3
58. Gastmeier P, Geffers C, Brandt C, et al. Effectiveness of a nationwide nosocomial infection surveillance system for reducing nosocomial infections. J Hosp Infect 2006;64:16-22
59. El Solh AA, Alhajhusain A. Update on the treatment of Pseudomonas aeruginosa pneumonia. J Antimicrob Chemother 2009;64(2):229-38
60. Gerding DN, Larson TA, Hughes RA, et al. Aminoglycoside resistance and aminoglycoside usage - 10 years of experience in one hospital. Antimicrob Agents Chemother 1991;35(7):1284-90
61. American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171(4):388-416
62. Niederman MS, Craven DE. Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia. Am J Respir Crit Care Med 2005;171(4):388-416
63. Korbila IP, Michalopoulos A, Rafailidis PI, et al. Inhaled colistin as adjunctive therapy to intravenous colistin for the treatment of microbiologically documented ventilator-associated pneumonia: a comparative cohort study. Clin Microbiol Infect 2010;16(8):1230-6
64. Kofteridis DP, Alexopoulou C, Valachis A, et al. Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilator-associated pneumonia: a matched case-control study. Clin Infect Dis 2010;51(11):1238-44
65. Griese M, Eismann C, Börner G, et al. A pharmacokinetics and safety comparison of a highly concentrated tobramycin solution with TOBI. J Aerosol Med Pulm Drug Deliv 2014;27(3):185-92
66. Hallal A, Cohn SM, Namias N, et al. Aerosolized tobramycin in the treatment of ventilator-associated pneumonia: a pilot study. Surg Infect (Larchmt) 2007;8(1):73-82
67. Lu Q, Yang J, Liu Z, et al. Nebulized Ceftazidime and Amikacin in Ventilator-associated Pneumonia Caused by Pseudomonas aeruginosa. Am J Respir Crit Care Med 2011;184(1):106-15
68. Abu-Salah T, Dhand R. Inhaled antibiotic therapy for ventilator-associated tracheobronchitis and ventilator-associated pneumonia: an update. Adv Ther 2011;28(9):728-47
69. Palmer LB, Smaldone GC, Chen JJ, et al. Aerosolized antibiotics and ventilator-associated tracheobronchitis in the intensive care unit. Crit Care Med 2008;36(7):2008-13
70. Adair CG, Gorman SP, Byers LM, et al. Eradication of endotracheal tube biofilm by nebulised gentamicin. Intensive Care Med 2002;28(4):426-31
71. Kang C-H, Tsai C-M, Wu T-H, et al. Colistin inhalation monotherapy for ventilator-associated pneumonia of Acinetobacter baumannii in prematurity. Pediatr Pulmonol 2014;49(4):381-8
72. Le Le J, Ashley ED, Neuhauser MM, et al. Consensus summary of aerosolized antimicrobial agents: application of guideline criteria. Pharmacotherapy 2010;30(6):562-84
73. Mohr AM, Sifri ZC, Horng HS, et al. Use of aerosolized aminoglycosides in the treatment of Gram-negative ventilatorassociated pneumonia. Surg Infect (Larchmt) 2007;8(3):349-58
74. Claridge JA, Edwards NM, Swanson J, et al. Aerosolized ceftazidime prophylaxis against ventilator-associated pneumonia in high-risk trauma patients: results of a double-blind randomized study. Surg Infect (Larchmt) 2007;8(1):83-90
75. Czosnowski QA, Wood GC, Magnotti LJ, et al. Adjunctive aerosolized antibiotics for treatment of ventilator-associated pneumonia. Pharmacotherapy 2009;29(9):1054-60
76. Luyt C-E, Clavel M, Guntupalli K, et al. Pharmacokinetics and lung delivery of PDDS-aerosolized amikacin (NKTR-061) in intubated and mechanically ventilated patients with nosocomial pneumonia. Crit Care 2009;13(6):1-10
77. Niederman M, Chastre J, Corkery K, et al. BAY41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with Gram-negative pneumonia. Intensive Care Med 2012;38(2):263-71
78. Luyt C-E, Eldon MA, Stass H, et al. Pharmacokinetics and tolerability of amikacin administered as BAY41-6551 aerosol in mechanically ventilated patients with gram-negative pneumonia and acute renal failure. J Aerosol Med Pulm Drug Deliv 2011;24(4):183-90
79. Gander S, Kinnaird A, Finch R. Telavancin: in vitro activity against staphylococci in a biofilm model. J Antimicrob Chemother 2005;56(2):337-43
80. LaPlante KL, Mermel LA. In vitro activities of telavancin and vancomycin against biofilm-producing Staphylococcus aureus, S. epidermidis, and Enterococcus faecalis strains. Antimicrob Agents Chemother 2009;53(7):3166-9
81. Smith K, Gemmell CG, Lang S. Telavancin shows superior activity to vancomycin with multidrug-resistant Staphylococcus aureus in a range of in vitro biofilm models. Eur J Clin Microbiol Infect Dis 2013;32(10):1327-32
82. McConeghy KW, LaPlante KL. In vitro activity of tigecycline in combination with gentamicin against biofilm-forming Staphylococcus aureus. Diagn Microbiol Infect Dis 2010;68(1):1-6
83. Draghi DC, Benton BM, Krause KM, et al. Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States. Antimicrob Agents Chemother 2008;52(7):2383-8
84. Krause KM, Renelli M, Difuntorum S, et al. In vitro activity of telavancin against resistant gram-positive bacteria. Antimicrob Agents Chemother 2008;52(7):2647-52
85. Biel MA, Sievert C, Usacheva M, et al. Reduction of Endotracheal Tube Biofilms Using Antimicrobial Photodynamic Therapy. Lasers Surg Med 2011;43(7):586-90
86. Eierhoff T, Bastian B, Thuenauer R, et al. A lipid zipper triggers bacterial invasion. Proc Natl Acad Sci USA 2014;111(35):12895-900
87. Chemani C, Imberty A, de Bentzmann S, et al. Role of LecA and LecB lectins in Pseudomonas aeruginosa-induced lung injury and effect of carbohydrate ligands. Infect Immun 2009;77(5):2065-75
88. Bucior I, Abbott J, Song Y, et al. Sugar administration is an effective adjunctive therapy in the treatment of Pseudomonas aeruginosa pneumonia. Am J Physiol Lung Cell Mol Physiol 2013;305(5):L352-63
89. Boukerb AM, Rousset A, Galanos N, et al. Antiadhesive Properties of Glycoclusters against Pseudomonas aeruginosa Lung Infection. J Med Chem 2014;57(24):10275-89
90. Jain J, Arora S, Rajwade JM, et al. Silver nanoparticles in therapeutics: development of an antimicrobial gel formulation for topical use. Mol Pharm 2009;6(5):1388-401
91. Dallas P, Sharma VK, Zboril R. Silver polymeric nanocomposites as advanced antimicrobial agents: classification, synthetic paths, applications, and perspectives. Adv Colloid Interface Sci 2011;166(1-2):119-35
92. Roe D, Karandikar B, Bonn-Savage N, et al. Antimicrobial surface functionalization of plastic catheters by silver nanoparticles. J Antimicrob Chemother 2008;61(4):869-76
93. Kalishwaralal K, BarathManiKanth S, Pandian SRK, et al. Silver nanoparticles impede the biofilm formation by Pseudomonas aeruginosa and Staphylococcus epidermidis. Colloids Surf B Biointerfaces 2010;79(2):340-4
94. Kittler S, Greulich C, Diendorf J, et al. Toxicity of Silver Nanoparticles Increases during Storage Because of Slow Dissolution under Release of Silver Ions. Chem Mater 2010;22(16):4548-54
95. Kora AJ, Arunachalam J. Assessment of antibacterial activity of silver nanoparticles on Pseudomonas aeruginosa and its mechanism of action. World J Microb Biot 2011;27(5):1209-16
96. Bjarnsholt T, Kirketerp-MØller K, Kristiansen S, et al. Silver against Pseudomonas aeruginosa biofilms. APMIS 2007;115(8):921-8
97. Melaiye A, Youngs WJ. Silver and its application as an antimicrobial agent. Expert Opin Ther Pat 2005;15(2):125-30
98. Dror-Ehre A, Adin A, Markovich G, Mamane H. Control of biofilm formation in water using molecularly capped silver nanoparticles. Water Res 2010;44(8):2601-9
99. Park H-J, Park S, Roh J, et al. Biofilm-inactivating activity of silver nanoparticles: a comparison with silver ions. J Ind Eng Chem 2013;19(2):614-19
100. Fabrega J, Renshaw JC, Lead JR. Interactions of silver nanoparticles with Pseudomonas putida biofilms. Environ Sci Technol 2009;43(23):9004-9
101. Leid JG, Ditto AJ, Knapp A, et al. In vitro antimicrobial studies of silver carbene complexes: activity of free and nanoparticle carbene formulations against clinical isolates of pathogenic bacteria. J Antimicrob Chemother 2012;67(1):138-48
102. Chaudhari PR, Masurkar SA, Shidore VB, Kamble SP. Effect of biosynthesized silver nanoparticles on Staphylococcus aureus biofilm quenching and prevention of biofilm formation. Nano-Micro Lett 2012;4(1):34-9
103. Namasivayam SKR, Christo BB, Arasu SMK, et al. Anti biofilm effect of biogenic silver nanoparticles coated medical devices against biofilm of clinical isolate of Staphylococcus aureus. Global J Med Res 2013;13:3
104. Feng QL, Wu J, Chen GQ, et al. A mechanistic study of the antibacterial effect of silver ions on Escherichia coli and Staphylococcus aureus. J Biomed Mater Res 2000;52(4):662-8
105. Fayaz AM, Balaji K, Girilal M, et al. Biogenic synthesis of silver nanoparticles and their synergistic effect with antibiotics: a study against gram-positive and gram-negative bacteria. Nanomedicine 2010;6(1):103-9
106. Wirth SM, Lowry GV, Tilton RD. Natural organic matter alters biofilm tolerance to silver nanoparticles and dissolved silver. Environ Sci Technol 2012;46(22):12687-96
107. Quirynen M, Van Der Mei HC, Bollen CML, et al. An in vivo study of the influence of the surface roughness of implants on the microbiology of supra- and subgingival plaque. J Dent Res 1993;72(9):1304-9
108. Sousa C, Teixeira P, Oliveira R. Influence of Surface Properties on the Adhesion of Staphylococcus epidermidis to Acrylic and Silicone. Int J Biomater 2009;2009:718017
109. Tang H, Cao T, Liang X, et al. Influence of silicone surface roughness and hydrophobicity on adhesion and colonization of Staphylococcus epidermidis. J Biomed Mater Res A 2009;88A(2):454-63
110. Triandafillu K, Balazs DJ, Aronsson BO, et al. Adhesion of Pseudomonas aeruginosa strains to untreated and oxygen-plasma treated poly(vinyl chloride) (PVC) from endotracheal intubation devices. Biomaterials 2003;24(8):1507-18
111. Lopez-Lopez G, Pascual A, Perea EJ. Effect of plastic catheter material on bacterial adherence and viability. J Med Microbiol 1991;34(6):349-53
112. Balazs DJ, Triandafillu K, Chevolot Y, et al. Surface modification of PVC endotracheal tubes by oxygen glow discharge to reduce bacterial adhesion. Surf Interface Anal 2003;35(3):301-9
113. Allison KR, Brynildsen MP, Collins JJ. Metabolite-enabled eradication of bacterial persisters by aminoglycosides. Nature 2011;473(7346):216-20
114. Hammond A, Dertien J, Colmer-Hamood JA, et al. Serum Inhibits P. aeruginosa Biofilm Formation on Plastic Surfaces and Intravenous Catheters. J Surg Res 2010;159(2):735-46
115. Chung KK, Schumacher JF, Sampson EM, et al. Impact of engineered surface microtopography on biofilm formation of Staphylococcus aureus. Biointerphases 2007;2(2):89-94
116. May R, Hoffman M, Reddy S. 12: micro-patterned surfaces for reducing bacterial biofilm formation on endotracheal tubes: a novel approach to decreasing the incidence of ventilator-associated pneumonia. Crit Care Med 2012;40(12):1-328
117. Olson ME, Harmon BG, Kollef MH. Silver-coated endotracheal tubes associated with reduced bacterial burden in the lungs of mechanically ventilated dogs. Chest 2002;121(3):863-70
118. Berra L, De Marchi L, Yu Z-X, et al. Endotracheal tubes coated with antiseptics decrease bacterial colonization of the ventilator circuits, lungs, and endotracheal tube. Anesthesiology 2004;100(6):1446-56
119. Rello J, Kollef M, Diaz E, et al. Reduced burden of bacterial airway colonization with a novel silver-coated endotracheal tube in a randomized multiple-center feasibility study. Crit Care Med 2006;34(11):2766-72
120. Berra L, Kolobow T, Laquerriere P, et al. Internally coated endotracheal tubes with silver sulfadiazine in polyurethane to prevent bacterial colonization: a clinical trial. Intensive Care Med 2008;34(6):1030-7
121. Berra L, Curto F, Li Bassi G, et al. Antimicrobial-coated endotracheal tubes: an experimental study. Intensive Care Med 2008;34(6):1020-9
122. Rello J, Afessa B, Anzueto A, et al. Activity of a silver-coated endotracheal tube in preclinical models of ventilator-associated pneumonia and a study after extubation. Crit Care Med 2010;38(4):1135-40
123. Asadinezhad A, Novák I, Lehocký M, et al. An in vitro bacterial adhesion assessment of surface-modified medical-grade PVC. Colloids Surf B Biointerfaces 2010;77(2):246-56
124. James NR, Jayakrishnan A. Surface thiocyanation of plasticized poly(vinyl chloride) and its effect on bacterial adhesion. Biomaterials 2003;24(13):2205-12
125. Hartmann M, Guttmann J, Müller B, et al. Reduction of the bacterial load by the silver-coated endotracheal tube (SCET), a laboratory investigation. Technol Health Care 1999;7(5):359-70
126. Kollef MH, Afessa B, Anzueto A, et al. Silver-coated endotracheal tubes and incidence of ventilator-associated pneumonia: the nascent randomized trial. JAMA 2008;300(7):805-13
127. Afessa B, Shorr AF, Anzueto AR, et al. Association between a silver-coated endotracheal tube and reduced mortality in patients with ventilator-associated pneumonia. Chest 2010;137(5):1015-21
128. Shorr AF, Zilberberg MD, Kollef M. Cost-effectiveness analysis of a silver-coated endotracheal tube to reduce the incidence of ventilator-associated pneumonia. Infect Control Hosp Epidemiol 2009;30(8):759-63